WO2014015377A1 - Lymphatic access system - Google Patents
Lymphatic access system Download PDFInfo
- Publication number
- WO2014015377A1 WO2014015377A1 PCT/AU2013/000822 AU2013000822W WO2014015377A1 WO 2014015377 A1 WO2014015377 A1 WO 2014015377A1 AU 2013000822 W AU2013000822 W AU 2013000822W WO 2014015377 A1 WO2014015377 A1 WO 2014015377A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lymph
- reservoir
- access system
- lymphatic
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/02—Access sites
- A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
- A61M2039/0258—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body for vascular access, e.g. blood stream access
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0405—Lymph
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/04—General characteristics of the apparatus implanted
Definitions
- the present invention relates to a lymphatic access system configured to direct lymph from a lymph duct in a subject to a lymph reservoir to allow access to the lymph in the lymph reservoir.
- the present invention relates to an implantable lymphatic access device.
- Typical vascular access systems are surgically implanted to allow intermittent access to an artery or vein to allow the withdrawal of blood and the administration of fluids or medications.
- Typical vascular access systems include a chamber having an outlet connected by a cannula to an artery or vein and a penetrable membrane for the chamber.
- the penetrable membrane is typically rubber or silicone and in use a needle is passed through the membrane into the chamber allowing fluid to be drawn through the needle or administered into the chamber through the needle.
- Lymph is a fluid formed by the draining of interstitial fluid into lymph capillaries. Lymph travels through lymph ducts to lymph nodes before joining larger lymph trunks, such as the thoracic duct, which drain into the circulation via major veins such as the left subclavian vein.
- the lymphatic system consists of the lymph capillaries, lymph ducts and lymph nodes.
- the lymphatic system may transport bacteria, which are captured and destroyed in lymph nodes. Metastatic cancer cells may also be transported via lymph.
- Lymph also transports fats from the digestive system. Lymph formed in the digestive system is also known as chyle and typically has a milky white appearance due to presence of triglycerides (fat) contained in spherical lipoproteins known as chylomicrons. Chyle is one of the primary means by which dietary fat enters the circulation.
- Lymph also contains lymphocytes. Lymph present in lymph nodes is typically richer in lymphocytes than lymph that has yet to reach the lymph nodes. Lymphocytes are mediators of the mammalian immune system.
- lymph vessels that returns lymph to the circulation is an open system with no active pump.
- lymph is not under pressure comparable to blood in the venous or arterial systems.
- Lymph movement is facilitated by peristalsis, valves in the lymph vessels, nearby arterial pulsation and movement of adjacent skeletal muscles.
- lymph does not flow backwards along the vessels because of the presence of valves. However if excessive pressure is applied to a lymph vessel, or pressure develops in the lymph system, this can contribute to edema.
- Typical vascular access systems are surgically implanted to allow intermittent access to an artery or a vein to allow the withdrawal of blood and the administration of fluids or medications.
- Such devices include a chamber (or 'reservoir 1 ) having an outlet connected by a conduit to an artery or vein.
- the chamber also has a penetrable membrane which is typically rubber or silicone and, in use, a needle is passed through the membrane into the chamber allowing fluid to be withdrawn via the needle or administered into the chamber through the needle.
- the chamber may be located external to the body, or it may be implanted to allow subcutaneous access.
- the vascular access system does not separate and prevent the mixing of inwardly and outwardly flowing materials.
- Lymph can be accessed by penetration of the axillary or inguinal lymph nodes by long needles or by surgical access to the thoracic duct or other portions of the lymph vessels. These methods are unsuitable for regular access to lymph. Penetration of lymph nodes yields only a small volume of lymph and is ineffective for administering fluid to the lymphatic system, and can cause significant discomfort to the subject.
- a lymphatic access system comprising:
- lymph reservoir for containing lymph, the lymph reservoir configured to allow access to lymph in the lymph reservoir;
- an inlet configured to divert lymph from a lymph duct in a subject to the lymph s reservoir
- an outlet configured to allow lymph in the lymph reservoir to return to a vessel in the subject
- a valve configured to control flow of lymph of the subject to or from the lymph reservoir.
- the lymphatic access system comprises an access fitting to allow access to lymph in the lymph reservoir.
- the access fitting may be a self-sealing membrane such as a septum, a cap or lid, a fitting for a syringe such as a male or female luer lock fitting.
- the access fitting may be associated with a further conduit.
- the further conduit may be configured to connect to a vessel at one end.
- the further conduit may be associated with a valve, for example to seal the further conduit when not in use.
- valves can be used in the system to control flow of lymph.
- the valve may be a ball valve, a butterfly valve, a pinch valve, an inflatable cuff, a gate valve, a diaphragm valve, a needle valve, or a check valve.
- the valve is a unidirectional valve.
- the lymphatic access system comprises a pressure release valve.
- the inlet includes an inlet conduit configured to connect to a lymph duct of a subject at one end and divert lymph from the lymph duct of the subject to the lymph reservoir.
- the inlet conduit is configured to connect to a lymph duct by anastomosis with the duct, catheterisation of the duct, or insertion into the duct.
- the inlet may be connected to a stent configured for placement within a lymph duct or secured by an exterior collar to a lymph duct, for example the thoracic duct.
- the outlet includes an outlet conduit configured to connect to a vessel of a subject at one end and allow lymph from the lymph reservoir to return to a vessel of the subject.
- the outlet conduit is configured to be connected to a vessel by an anastomosis with the vessel, catheterisation of the vessel or insertion into the vessel.
- the outlet may be connected to a stent configured for placement within a lymph duct or other vessel or secured by an exterior collar to the lymph duct or vessel.
- the vessel may be a lymph duct, vein or ureter.
- the lymph reservoir has two or more compartments capable of receiving lymph.
- the lymphatic access system includes a second reservoir in fluid communication with the first lymph reservoir.
- the second reservoir is configured to allow access to lymph in the second reservoir.
- the second reservoir includes an access fitting associated with the second reservoir to allow access to lymph in the second lymph reservoir.
- the second reservoir includes:
- an inlet configured to receive lymph from the first lymph reservoir; and an outlet configured to allow lymph to be removed from the second reservoir.
- the outlet includes a conduit configured to connect to a vessel of a subject at one end and allow lymph from the second reservoir to return to a vessel of the subject.
- the second reservoir includes a valve configured to control flow of lymph to or from the second reservoir.
- the lymph reservoir or the second reservoir may comprise more than one chamber.
- the lymph reservoir and/or the second reservoir may be divided by at least one valve, partition, baffle, or any combination thereof.
- the lymphatic access system can be made from any suitable biocompatible material. Typically the material will possess sufficient resilience to resist damage from needles or other devices that may be repeatedly inserted into the access system to access the lymph. Examples of biocompatible materials include plastics and metals. Biocompatible plastics are advantageous as they can be used with conventional fabrication techniques.
- the lymph reservoir is constructed from an elastomeric material capable of withstanding repeated punctures with a needle without leaking and which preferably seals after the needle is removed.
- the lymphatic access system may be implantable in a subject.
- the lymphatic access system is configured for subcutaneous implantation in a subject.
- the lymphatic access system is configured for percutaneous use.
- the subject is a mammal.
- the mammal preferably is a human, sheep, pig, rabbit or rat.
- kits comprising:
- At least one catheter configured to provide fluid communication between a lymph duct in a subject and the lymph reservoir of the lymphatic access system.
- the present invention provides a method for diverting lymph from a subject, the method comprising:
- the lymph may or may not have been processed before being returned to the subject.
- lymph in the reservoir is accessed through an access fitting of the reservoir.
- lymph in the lymph reservoir is returned to the subject via the outlet.
- the lymph may be returned to the lymphatic system via a lymph vessel or diverted to the venous or urinary system for natural processing and removal from the subject.
- the lymph accessed from the lymph reservoir is separated, fractionated, refined, or purified.
- the diverted lymph within the lymph reservoir is separated, fractionated, refined, metabolised, purified, and or altered by pharmacological, biochemical, centrifugal and or molecular means prior to returning the lymph.
- the accessed lymph is altered by pharmacological, biochemical, physical or molecular means.
- the pharmacological alteration includes drug treatment, immuno-therapy, or transfection of a biological material.
- the lymph within the lymph reservoir is diverted in order to diagnose or respond to the presence of a pathological disease or condition.
- the pathological disease or condition is selected from the group consisting of cardiovascular disease,
- hyperlipidaemia diabetes, infectious disease, obesity, metabolic syndrome associated with obesity, organ failure, autoimmune disease, transplant rejection, malignancies including de novo or recurrent malignancies, neurodegenerative diseases, organ failure, sepsis, shock lung, and food allergies.
- the neurodegenerative disease is Alzheimer's disease or dementia.
- the organ failure is kidney failure, cardiac failure or liver failure.
- the pharmacological alteration includes incorporation of a drug, transfection of a biological material or immuno-therapy.
- the present invention relates to a system for accessing and processing lymph.
- the system is configured to direct lymph from a lymph vessel in a subject in a controlled fashion to allow acquisition and processing of the lymph with the option of returning some or all of the processed lymph to the subject.
- the system may include a component to access lymph including a device or devices to facilitate physical access to the lymphatic portion of the vasculature, for example a stent.
- the system also includes conduits and accessible reservoir(s) to facilitate acquisition of the contained lymphatic fluid.
- the system may include processing components described in greater detail below. These processing components can assist in processing the lymph for therapeutic purposes.
- the apparatus may be positioned external to a subject.
- the apparatus may be located subcutaneously for percutaneous use. That is any or all of the components comprising the system may be implantable and interchangeable.
- Figure 1 is a schematic view of an embodiment of the lymphatic access system of the invention.
- Figure 2 is a schematic view of an embodiment of the lymphatic access system of the invention.
- Figure 3 is a schematic view of an embodiment of the lymphatic access system of the invention showing a reservoir having two compartments.
- Figure 4 is a schematic view of an embodiment of the lymphatic access system of the invention with two reservoirs.
- Figure 5 is a schematic view of an embodiment of the lymphatic access system of the invention for percutaneous or transvenous use that obviates the need for a transmural connection. Definitions
- the term 'access system' as used in this specification refers to a device used to divert or permit flow of a fluid from one region back to another region within the same fluid conduit.
- valve' refers to any device for controlling the passage of fluid.
- pressure release valve' refers to any device for controlling the passage of fluid in response to pressure.
- 'stent' refers a tubular support device.
- the term 'subject' includes humans and individuals of any species of social, economic or research importance including but not limited to members of the genus ovine, bovine, equine, porcine, feline, canine, primates (including human and non-human primates), rodents, murine, caprine, leporine, and avian.
- the subject is a human.
- lymphatic access system 10 is provided.
- the lymphatic access system 10 includes a lymph reservoir 12 for containing lymph.
- the lymph reservoir 12 includes inlet 14 configured to direct lymph from a lymph duct in a subject to the lymph reservoir 12. In use, the inlet 14 provides fluid
- the lymphatic access system 10 can also include a valve 20 to control flow of lymph of the subject to or from the lymph reservoir 12.
- the lymphatic access system 0 also includes a pressure release valve 22.
- the lymphatic access system 10 may be made from any suitable biocompatible material. Typically the material will possess sufficient resilience to resist damage from needles or other devices that may be repeatedly inserted into the access system to access the lymph. Examples of biocompatible materials include plastics and metals. Biocompatible plastics are advantageous as they can be used with conventional fabrication techniques.
- the lymph reservoir 2 is constructed from an elastomeric material capable of withstanding repeated punctures with a needle without leaking and which preferably seals after the needle is removed.
- the inlet 14 includes a conduit 24 to connect to a lymph duct of a subject at one end and divert lymph from the lymph duct of the subject to the lymph reservoir 12.
- the outlet 18 typically includes an outlet conduit 26 configured to connect to a vessel of a subject at one end and allow lymph from the lymph reservoir 12 to return to the vessel of the subject.
- the lymph reservoir 12 may have two or more compartments 28 capable of receiving lymph.
- the lymph reservoir 2 has compartments 28 formed by the presence of one or more valves, partitions, baffles, support structures 30 or any combination thereof.
- the access system 10 includes a second reservoir 32 in fluid communication with the lymph reservoir 12.
- the second reservoir 32 includes an inlet 34 configured to receive lymph from the lymph reservoir 12 and an outlet 18 configured to allow lymph to be removed from the second reservoir 32.
- the second reservoir 32 may be connected to the lymph reservoir 12 by a conduit 38.
- the outlet 18 may be connected to the inlet 34 of the second reservoir 32.
- the second reservoir 32 includes a valve 40 configured to control flow of lymph to or from the second reservoir 32.
- the reservoir may be any volume considered useful by those skilled in the art.
- Preferred reservoir volumes are between 5 ml and 500 ml.
- the reservoir volume may be about 5 ml, or about 25 ml, or about 50 ml, or about 75 ml, or about 100 ml, or about 125 ml, or about 150 ml, or about 175 ml, or about 200 ml, or about 225 ml, or about 250 ml, or about 275 ml, or about 300 ml, or about 325 ml, or about 350 ml, or about 375 ml, or about 400 ml, or about 425 ml, or about 450 ml, or about 475 ml, or about 500 ml.
- the length of the conduits is typically between about 10 cm and 1 meter.
- the conduit length may about 10 cm, or about 20 cm, or about 30 cm, or about 40 cm, or about 50 cm, or about 60 cm, or about 70 cm, or about 80 cm, or about 90 cm, or about 1 meter.
- the length may be altered by any means known in the art to suit the anatomy of the subject to which the lymphatic access system 10 is provided.
- the lumen size of the conduits is typically between about 1 mm and about 4 mm.
- the lumen size may be about 1 mm, or about 1.5 mm, or about 2 mm, or about 2.5 mm, or about 3 mm, or about 3.5 mm, or about 4 mm.
- the subject may be an animal.
- the subject is a mammal.
- the term 'mammal' includes humans and individuals of any species of social, economic or research importance including but not limited to members of the genus ovine, bovine, equine, porcine, feline, canine, primates (including human and non-human primates), rodents, murine, caprine, leporine, and avian.
- the mammal is a human.
- the lymphatic access system 10 is also suitable for animals such as laboratory animals including mice, rats, rabbits, dogs, sheep, pigs and cows for medical or veterinary research use.
- the lymphatic access system 10 may be provided to a subject using minimally invasive techniques known in the art and preferably with the assistance of magnetic resonance imaging (MRI) to reveal the course of the lymphatic duct in the subject.
- the lymphatic access system 10 may be assembled during installation into the subject.
- the inlet conduit 24 may be connected to the lymph duct before connection to the inlet of the lymph reservoir 12.
- the outlet 18 may then be connected to a vessel directly or via an outlet conduit 26. It is envisaged that where the lymphatic access system 10 is assembled during installation in the body, the order of assembly of the components will be at the discretion of the physician performing the implantation to achieve optimum placement of the lymphatic access system.
- confirmation that the lymphatic access system 10 is operating may be achieved by for example MRI or by testing the lymphatic access system 10 by removal of lymph from the lymph reservoir 12.
- the lymphatic access system 10 can be implantable in a subject and typically surgically implanted, preferably such that it is entirely subcutaneous.
- the lymphatic access system 10 may be fully implantable into the subject such that the access fittings, and/or reservoir(s) are located subcutaneously so as to allow access to the lymph in the reservoir through the skin for example using a needle. That is, the lymph reservoir 12 and/or the second reservoir 32 may be configured for percutaneous use.
- the lymphatic access system 10 is implanted in the extra-thoracic region of a subject and the inlet conduit 24 is connected to the thoracic duct.
- the outlet conduit 26 may be connected to the junction of the left jugular and subclavian veins.
- the lymphatic access system 10 is configured such that the lymph reservoir 12 and/or the second reservoir 32 are external to a subject.
- the inlet conduit 24 may protrude through the skin of a subject and connect with the inlet of the lymph reservoir 12 that is external to the subject.
- the outlet 18 may be associated with a conduit 26, for example the outlet conduit 26 that penetrates the skin of a subject to allow return of the lymph to the vessel.
- the access fitting 16 may be a self-sealing penetrable membrane such as a septum.
- the access fitting 16 may be a cap or lid, a fitting for a syringe such as a male or female luer lock fitting.
- the access fitting 16 may be associated with a further conduit (not shown).
- the further conduit may be configured to connect to a vessel at one end.
- the further conduit may be associated with a valve (not shown) such as an inflatable cuff.
- the valve 20 may seal the further conduit when not in use.
- the valve 20 or pressure release valve 22 may be a ball valve, a butterfly valve, a pinch valve, an inflatable cuff, a gate valve, a diaphragm valve, a needle valve, a check valve.
- the valve 20, or pressure release valve 22 is a unidirectional valve.
- the lymph reservoir 12 and/or the second reservoir 32 may include more than one chamber. Fpr example, and with reference to Figure 3, the lymph reservoir is divided into compartments 28 by at least one valve, or at least partition, baffle, support structure 30, or any combination thereof.
- the inlet conduit 14 is configured to connect to a lymph duct by any suitable means known in the art. In one embodiment, the inlet conduit 14 is configured to connect to a lymph duct by anastomosis with the duct, catheterisation of the duct, or insertion into the duct. Typically this connection is made surgically.
- the outlet conduit 18 and/or the further conduit may be configured to connect to a vessel by any suitable means known in the art.
- the outlet conduit 18 and/or further conduit is adapted to be connected to a vessel for example by an anastomosis with the vessel, catheterisation of the vessel or insertion into the vessel. Typically this connection would also be made surgically.
- the outlet conduit 18 and/or the further conduit may be connected with any vessel.
- the vessel may be a lymph duct, vein or ureter.
- the inlet conduit 14 may be connected to a stent (not shown) configured for placement within a lymph duct.
- the outlet conduit 24 may be connected to the stent (not shown) or to another stent (not shown) configured for placement within a lymph duct or other vessel.
- the lymphatic access system 10 shown in Figure 4 in operation, is connected to a lymphatic duct such as the thoracic duct.
- a lymphatic duct such as the thoracic duct.
- the inlet 14 connects the thoracic duct to the lymph reservoir 12.
- a connecting conduit 38 connects the lymph reservoir and a second reservoir 32.
- the second reservoir 32 is connected with the thoracic duct by an outlet 18.
- Flow of lymph between the lymph reservoir 12 and the second reservoir 32 is controlled by a valve 40.
- the valve 40 is associated with the connecting conduit 34 which provides fluid communication between the lymph reservoir 12 and the second reservoir 32.
- an optional feature of the lymphatic access system 10 is a valve 20 associated with either or both of the inlet conduit 24 and the outlet conduit 26 and is located proximal to the thoracic duct.
- the valve 20 is configured to isolate the lymphatic access system 10 from the thoracic duct, for example when the lymphatic access system 10 is not in use.
- the lymphatic access system 10 as shown in Figure 4 in operation, is connected to a lymphatic duct, such as the thoracic duct and the left subclavian vein.
- a lymphatic duct such as the thoracic duct and the left subclavian vein.
- the inlet 14 connects the thoracic duct to the lymph reservoir 12.
- a connecting conduit 34 connects the lymph reservoir 12 and a second reservoir 32.
- the second reservoir 32 is connected with the left subclavian vein by an outlet 18.
- Flow of lymph between the lymph reservoir 12 and the second reservoir 32 is controlled by a valve 40.
- the valve 40 is associated with the connecting conduit 34, which provides fluid communication between the lymph reservoir 12 and the second reservoir 32.
- an optional feature of the lymphatic access system 10 is a pressure release valve 22, illustrated as associated with the outlet conduit 26 and is located proximal to the thoracic duct.
- the pressure release valve 22 is configured to release lymph from the lymphatic access system 10 once a predetermined pressure is reached in the reservoir 12.
- the inlet conduit 24 and the outlet conduit 26 may be a multiple lumen catheter 48 inserted into the thoracic duct via percutaneous and transvenous techniques with entry for example from the left subclavian vein and held in place using an inflatable balloon 50 around the catheter.
- the lymphatic access system 10 may include a biocompatible, double lumen, balloon catheter 48 that may be delivered into the lumen of a major lymphatic trunk by percutaneous, transvenous techniques.
- the catheter 48 obviates the need for transmural connection. It provides an afferent conduit via lumen and an efferent conduit via lumen.
- the direction of flow of lymph may be controlled by inflation or deflation of inflatable balloon 50 which may be a lumen-occluding balloon.
- this catheter 48 may be withdrawn by means of deflation of inflatable balloon 50.
- the catheter 48 may be introduced into the lumen of a lymphatic trunk via percutaneous, transvenous techniques known in the art.
- the present invention also relates to various uses of a system for accessing and processing lymph.
- the lymphatic access system 10 is configured to direct lymph from a lymph vessel in a subject in a controlled fashion to allow acquisition and processing of the lymph with the option of returning some or all of the processed lymph to the subject.
- the lymphatic access system 10 may optionally include apparatus to process the lymph for therapeutic and/or diagnostic purposes. Any or all of the components comprising the system may be implantable and interchangeable.
- Optional processing apparatus can include means to process the lymph for therapeutic purposes for example to remove lipids or metastatic cells or to isolate fractions of lymph or populations of cells in the lymph.
- the lymphatic access system 10 may be positioned external to a subject.
- the lymphatic access system 10 may be located subcutaneously for percutaneous use. That is, any or all of the components comprising the system may be implantable and interchangeable.
- use of the lymphatic access system 10 may include processing to remove lipid from chylous lymph.
- the lipid-treatment can be configured to remove dietary lipid in the form of chylomicrons from chylous lymph.
- Beads coated with lipid-removing material(s) can be used and include for example anti-apo B antibodies, dextran sulphate cellulose, polyacrylate or other substances known in the art to be suitable for binding lipid.
- the beads coated with lipid removing materials can be capable of regeneration by the introduction of an eluting solution or solutions.
- the lymphatic access system 10 may can be used to acquire lymphocytes, chylomicrons from chylous lymph or the incorporation of substances including drugs, biological agents (such as antibodies) or genetic materials for site-specific delivery.
- Use of the lymphatic access system 10 to acquire lymphocytes or chylomicrons as the acquisition of endogenous chylomicrons or lymphocytes will provide a substrate for incorporation of drugs, genetic material, biological agents such as antibodies, oligonucleotides and other therapeutic agents.
- the therapeutically modified lymphocytes and/or chylomicrons can then be re-introduced to a subject with the expectation that, in the case of modified chylomicrons, they will selectively be taken up by the liver.
- the use of endogenous lipoproteins and/or lymphocytes should prevent the development of an immune response against the vehicle carrying the therapeutic agent. This will permit the repeated administration of the agent concerned.
- the lymphatic access system 10 may can be used to retain and process the lymphocytes that are present within lymph fluid. In use, this enables the lymphatic fluid to be filtered so that lymphocytes are retained temporarily for purposes including incubation with therapeutic agents such as antibodies or
- use of the lymphatic access system 10 may include removing excess fluid and noxious substances in order to alleviate organ insufficiency such as liver failure, renal failure and cardiac failure.
- the lymphatic fluid collected by the lymphatic access system 10 can be filtered so that fluid and low molecular weight toxins are eliminated whilst lymphocytes and proteins are retained and continually or episodically returned to the circulation in order to maintain nutrition and immune sufficiency.
- the lymphatic access system 10 can be used to remove noxious substances which contribute to shock, adult respiratory distress syndrome sepsis and severe illness.
- the lymphatic access system 10 enables the lymphatic fluid in the system to be eliminated or processed to selectively retain favourable elements.
- This lymphatic access system may also be applied to the management of severe food allergies. In the context of serious food allergy the allergenic dietary proteins are retained by the apparatus and prevented from reaching the systemic circulation.
- valves, taps, and flow control devices Appropriate isolation of fluids can be maintained by appropriately incorporated one-way valves, taps, and flow control devices.
- the valves, taps and flow control devices may be activated remotely, including external activation of internally implanted valves, taps and flow control devices.
- the control of flow prevents mixing of inwardly (unprocessed) and outwardly flowing (processed) lymph.
- the lymphatic access system 10 can be used for the acquisition of lymph and/or lymph components for diagnostic pathology testing by means of biochemical, serological, microbiological, genetic, cytological, immunological, histopathological, flow cytometry or other methods known in the art.
- the sample for analysis may be acquired by percutaneous insertion of a needle and aspiration of the sample from the lymph reservoir 12.
- the lymphatic access system 10 is connected to the thoracic duct, which drains all regions except for the right arm, shoulder, neck and head. Therefore the lymph from the thoracic duct can be used to monitor the status of all other regions of the body for signs of pathology, particularly metastasis of malignancies. Monitoring of regions that are not drained by the thoracic duct may be undertaken by connection of the lymphatic access system 10 to another major lymph trunk.
- the second reservoir 32 or compartment 28 may contain, for example, affinity beads which may sequester malignant cells (or other targets), and which may provide samples of those beads for analysis or treatment.
- the analysis may be designed to detect the presence of bead-bound malignant cells (or other targets) and thereby identify the possibility of metastasis (or other pathological processes) and the need for treatment of the source.
- the present invention provides a lymphatic access system 10 which can divert lymph flow and allow access to the lymph. Additionally, in some embodiments a dual reservoir of the lymphatic access system 10 is particularly suitable for procedures requiring simultaneous inflow and outflow of lymph.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- External Artificial Organs (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261675177P | 2012-07-24 | 2012-07-24 | |
US61/675,177 | 2012-07-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014015377A1 true WO2014015377A1 (en) | 2014-01-30 |
Family
ID=49996428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2013/000822 WO2014015377A1 (en) | 2012-07-24 | 2013-07-24 | Lymphatic access system |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014015377A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140155806A1 (en) * | 2012-12-05 | 2014-06-05 | Ming-Huei Cheng | Device for draining lymph into vein |
WO2015200797A3 (en) * | 2014-06-26 | 2016-02-18 | The Trustees Of The University Of Pennsylvania | Devices and methods for alleviating lymphatic system congestion |
CN105497999A (en) * | 2016-01-25 | 2016-04-20 | 张伟 | Lymph purification therapeutic apparatus |
WO2016083784A1 (en) * | 2014-11-24 | 2016-06-02 | Imperial Innovations Limited | Lymph node replacement construct |
WO2018087642A1 (en) * | 2016-11-14 | 2018-05-17 | Empire Technology Development Llc | Systems and methods for reservoir with inlet-outlet connectors having unidirectional valves |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372182B1 (en) * | 1998-05-01 | 2002-04-16 | Aalto Scientific Ltd | Integrated body fluid collection and analysis device with sample transfer component |
US6616623B1 (en) * | 1997-07-02 | 2003-09-09 | Idializa Ltd. | System for correction of a biological fluid |
EP1671666A1 (en) * | 2004-12-20 | 2006-06-21 | Karl-Dieter Reusch | Apparatus for applying a solution to a blood or lymph vessel and use thereof |
US20070075008A1 (en) * | 2003-10-14 | 2007-04-05 | Kutushov Mikhail V | System for correcting biological fluid |
US20130012909A1 (en) * | 2011-07-08 | 2013-01-10 | Pinto Giovanni | Device for medical use for collecting and transit of blood, blood derivatives and/or filler fluids, and an extracorporeal circuit comprising the device |
-
2013
- 2013-07-24 WO PCT/AU2013/000822 patent/WO2014015377A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6616623B1 (en) * | 1997-07-02 | 2003-09-09 | Idializa Ltd. | System for correction of a biological fluid |
US6372182B1 (en) * | 1998-05-01 | 2002-04-16 | Aalto Scientific Ltd | Integrated body fluid collection and analysis device with sample transfer component |
US20070075008A1 (en) * | 2003-10-14 | 2007-04-05 | Kutushov Mikhail V | System for correcting biological fluid |
EP1671666A1 (en) * | 2004-12-20 | 2006-06-21 | Karl-Dieter Reusch | Apparatus for applying a solution to a blood or lymph vessel and use thereof |
US20130012909A1 (en) * | 2011-07-08 | 2013-01-10 | Pinto Giovanni | Device for medical use for collecting and transit of blood, blood derivatives and/or filler fluids, and an extracorporeal circuit comprising the device |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140155806A1 (en) * | 2012-12-05 | 2014-06-05 | Ming-Huei Cheng | Device for draining lymph into vein |
US9504810B2 (en) * | 2012-12-05 | 2016-11-29 | Ming-Huei Cheng | Device for draining lymph into vein |
WO2015200797A3 (en) * | 2014-06-26 | 2016-02-18 | The Trustees Of The University Of Pennsylvania | Devices and methods for alleviating lymphatic system congestion |
US10639458B2 (en) | 2014-06-26 | 2020-05-05 | The Trustees Of The University Of Pennsylvania | Devices and methods for alleviating lymphatic system congestion |
WO2016083784A1 (en) * | 2014-11-24 | 2016-06-02 | Imperial Innovations Limited | Lymph node replacement construct |
CN107530158A (en) * | 2014-11-24 | 2018-01-02 | 詹姆斯·摩尔 | lymph node replacing structure |
US11071618B2 (en) | 2014-11-24 | 2021-07-27 | James Edward Moore, Jr. | Lymph node replacement construct |
EP4046596A1 (en) * | 2014-11-24 | 2022-08-24 | James Moore | Lymph node replacement construct |
CN105497999A (en) * | 2016-01-25 | 2016-04-20 | 张伟 | Lymph purification therapeutic apparatus |
WO2018087642A1 (en) * | 2016-11-14 | 2018-05-17 | Empire Technology Development Llc | Systems and methods for reservoir with inlet-outlet connectors having unidirectional valves |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014015377A1 (en) | Lymphatic access system | |
JP4202594B2 (en) | System and method for site-specific therapy | |
US7611480B2 (en) | Gastrointestinal bioreactor | |
US4911717A (en) | Intravasular artificial organ | |
Florey | Reactions of, and absorption by, lymphatics, with special reference to those of the diaphragm | |
US20060247605A1 (en) | Implantable dialysis access port | |
US20140012180A1 (en) | Peritoneal drain and infusion | |
JPH11513284A (en) | Method for accessing a cannula and artery implanted subcutaneously | |
JP2002536130A (en) | Systems and methods for removing holding fluid and injecting treatment fluid | |
JPH10506806A (en) | Artificial liver device and method | |
WO2006025950A1 (en) | Urethral sealing method and device | |
de Aquino et al. | Nonfunctional abdominal complications of the distal catheter on the treatment of hydrocephalus: an inflammatory hypothesis? Experience with six cases | |
US20140088567A1 (en) | Compositions and Methods for Removing Ascitic Fluid from the Abdomen | |
Rosenberg | Cerebrospinal fluid: Formation, absorption, markers, and relationship to blood–brain barrier | |
Ramaswamy et al. | Maintenance and recovery stages of postischemic acute renal failure in humans | |
US20200030585A1 (en) | Devices and Methods for Treating Congestive Heart Failure, Ascites, and Other Disorders Relating to Excess Bodily Fluid | |
US11504515B2 (en) | Access port system with self-adjusting catheter length | |
KR20180003879A (en) | Bioreactor system for decellularization of extracted organs and decellularization method through the same | |
Nyberg et al. | Cytotoxic immune response to a xenogeneic bioartificial liver | |
US20040059275A1 (en) | Fat extraction | |
CN105597175B (en) | A kind of haemodialysis equipment | |
Ohkuma | Dermal lymph and lymphatics | |
Fadem | Available Treatments If My Kidneys Do Fail | |
US10974024B1 (en) | Flushable multi-lumen catheter device and method of use | |
JP2676298B2 (en) | Animal test method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13823164 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WPC | Withdrawal of priority claims after completion of the technical preparations for international publication |
Ref document number: 61/675,177 Country of ref document: US Date of ref document: 20150202 Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13823164 Country of ref document: EP Kind code of ref document: A1 |